Dozens of new PubMed papers touch peptides, functional biomarkers, or clinical decision support every week. Almost none will change what a prescriber does on Monday morning. Two or three might. The problem is that nobody has time to figure out which is which.
Scriptura's Clinical Evidence pillar runs a daily PubMed scan across the compounds and biomarkers that matter to longevity practice: BPC-157, TB-500, GLP-1 receptor agonists like semaglutide, tirzepatide, and retatrutide, growth hormone secretagogues (CJC-1295, ipamorelin, sermorelin, tesamorelin), thymosin peptides, KPV, LL-37, epithalon, DSIP, and the functional biomarkers we watch (hs-CRP, IL-6, TNF-alpha, HOMA-IR, HbA1c variability, methylation markers, organic acids, glycan age, and more).
For each article that actually changes clinical practice, the system writes a short delta note. What does this study change in the Sequence Method? Does it move dosing, cadence, or cautions? What is the suggested update for prescribers to review before the next visit?
You get signal, not another 40 tab research browser. And every recommendation the practice writes down carries a citation trail all the way back to the paper that supports it.
Written by the Scriptura Health clinical team. For clinician review only. Not medical advice.